Dr. Aseem Malhotra on statins: what the evidence says · JRE #1979
SUBJECT: STATINS
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
his department had taken over 200 million pounds at Oxford for doing research into statins from the drug industry. And they also kept the data commercially confidential.
What the evidence says 01 / RECORD
Malhotra's claim could not be adequately verified against an allowlisted primary or reputable-journalism source. Independent web reporting (not on the approved source list, including blog analyses of a 2014 CTSU funding disclosure and coverage of the 2013-2014 BMJ retraction dispute) indicates that Oxford's Clinical Trial Service Unit (CTSU), headed by Professor Sir Rory Collins, disclosed roughly 268 million pounds in industry grants over about two decades, with the statin manufacturer Merck alone contributing an estimated 217.5 million pounds, a total that would exceed 200 million pounds as Malhotra states. The same reporting describes the Cholesterol Treatment Trialists (CTT) Collaboration, housed at CTSU, as holding individual trial participant data under agreements that restrict release to outside researchers, consistent with a commercially confidential description. However, the BMJ pages that document this dispute directly are inaccessible to automated verification (blocked by a bot-protection challenge), and no source meeting the site's evidentiary allowlist could be confirmed to state the 200 million pound figure or attribute it specifically to Collins's unit. The broader pattern of restricted statin trial data access is corroborated by an allowlisted BMJ-published commentary, but the specific monetary figure and its direct attribution remain unconfirmed against an approved source in this review.